USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: INNOVATIVE BIOLOGICS, INC
City: HERNDON
State: VA
Zip+4: 20171 3296
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $505,595.00 3
SBIR Phase II $4,398,456.00 3

Award List:

SMALL MOLECULE BLOCKERS OF B. ANTHRACIS TOXIN

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Vladimir A. Karginov
Award Amount: $106,498.00
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this SBIR proposal is the identification of small molecules capable of blocking the cytotoxic action of Bacillus anthracis lethal toxin by blocking the transmembrane pore formed by the protective antigen component of the toxin. Such molecules… More

Small Molecule Blockers of B. anthracis Toxin

Award Year / Program / Phase: 2004 / SBIR / Phase II
Agency: HHS
Principal Investigator: Vladimir A. Karginov
Award Amount: $1,703,293.00
Abstract:
DESCRIPTION (provided by investigator): Results from our SBIR Phase I project demonstrated that beta-cyclodextrin derivatives designed to block the trans-membrane channel formed by B. anthracis protective antigen (PA) can inhibit the cytotoxic effects of anthrax toxin at low micromolar… More

Small Molecule Inhibitors of C. perfringens Epsilon-Toxin

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Vladimir A. Karginov
Award Amount: $99,097.00
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this SBIR Phase I proposal is to find compounds that inhibit C. perfringens epsilon-toxin action using a novel approach for the inactivation of pore-forming toxins developed at Innovative Biologics, Inc. It is based on the blocking of the… More

Small Molecule Inhibitors of C. perfringens Epsilon-Toxin

Award Year / Program / Phase: 2008 / SBIR / Phase II
Agency: HHS
Principal Investigator: Vladimir A. Karginov
Award Amount: $741,493.00
Abstract:
DESCRIPTION (provided by applicant): C. perfringens epsilon-toxin (ETX) is a potential biological weapon included in the list of category B priority agents. The overall goal of this proposal is to identify and perform in vivo testing of new inhibitors of E TX using a novel approach for the… More

In vivo Testing of S. aureus alpha-Hemolysin Inhibitors

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Vladimir A. Karginov
Award Amount: $300,000.00
Abstract:
DESCRIPTION (provided by applicant): We have recently demonstrated that alpha-hemolysin produced by S. aureus plays a key role in the pathogenesis of staphylococcal pneumonia, and identified beta-cyclodextrin derivatives that potently inhibit the cytotoxic effects of this secreted bacterial toxin.… More

Small Molecule Blockers of B. anthracis Toxin

Award Year / Program / Phase: 2009 / SBIR / Phase II
Agency: HHS
Principal Investigator: Vladimir A. Karginov
Award Amount: $1,953,670.00
Abstract:
DESCRIPTION (provided by applicant): The results from our SBIR Phase II project demonstrated that ?-cyclodextrin derivatives designed to block the transmembrane channel formed by B. anthracis protective antigen can inhibit the cytotoxic effects of anthrax toxin at low- and sub-micromolar… More